March 2005
Worldwide Biotech;Mar2005, Vol. 17 Issue 3, p2
Trade Publication
Deals with the decision of Avexa Ltd. to in-license the Phase II HIV drug SPD754 from Shire Pharmaceuticals Group PLC in March 2005. Schedule for the release of the drug in the U.S. market; Impact of the production of SPD754 on the financial performance of the firm; Ability of the drug to selectively inhibit the HIV replication enzyme reverse transcriptase.


Related Articles

  • Renovo Licenses Juvista To Shire In Potential $825M Deal. Morrison, Trista // BioWorld Today;6/21/2007, Vol. 18 Issue 120, p1 

    The article reports that Renovo Group plc has licensed anti-scarring drug Juvista to Shire plc in a deal worth up to $825 million. Shire succeeded by offering a package that includes $125 million up front. In addition to the up front payment, Renovo may receive up to $175 million in regulatory...

  • Renovo Licenses Juvista To Shire In Potential $825M Deal. Morrison, Trista // BioWorld International;6/27/2007, Vol. 12 Issue 26, p7 

    The article reports that Renovo Group plc has licensed anti-scarring drug Juvista to Shire plc in a deal worth $825 million. Renovo chief executive officer (CEO) and founder Mark Ferguson, said that there was considerable interest in partnering Juvista, and that it was a competitive process. He...

  • Assets for Advantage. Looney, William // Pharmaceutical Executive;Feb2010, Vol. 30 Issue 2, p10 

    An introduction to the journal is presented in which the editor discusses an article on the survey from Hay Group on Sales Force Effectiveness, the profile of Shire Pharmaceuticals Group PLC, and the fourth annual choice of the Drug Brand of the Year.

  • INTUNIV.  // Physician Assistants' Prescribing Reference;Winter2009, Vol. 16 Issue 4, pA19 

    The article evaluates the medicine Intuniv from Shire Pharmaceuticals Group PLC.

  • Pharmaceuticals In Brief.  // Chemical Market Reporter;8/13/2001, Vol. 260 Issue 7, p8 

    Reports on the approval received by Shire Pharmaceuticals Group for Adderall XR drug.

  • Life Sciences in brief.  // Chemical Market Reporter;12/5/2005, Vol. 268 Issue 19, p37 

    The article presents news briefs related to the life sciences industry. IDM Pharma Inc. has agreed to sell specific assets of its infectious disease programs and other assets to Pharmexa AS for $12 million to focus on its five clinical-stage cancer programs. A biologics license application was...

  • SHIRES' OPTION FOR RIGHTS TO EMITASOL EXPIRES.  // Worldwide Biotech;Dec2001, Vol. 13 Issue 12, p1 

    Reports the expiration of Shire Pharmaceuticals Group's option to acquire the exclusive rights to market the intranasal metaclopramide Emitasol from Questcor Pharmaceuticals Inc. in North America. Information on emitasol and emesis; Views of the American Cancer Society on the drug; Details on...

  • NEWSLINE.  // MPR - Pharmacist's Edition;Spring2011, Vol. 5 Issue 1, pA.12 

    The article presents several drugs and vitamins for various diseases including Intuniv from Shire Pharmaceuticals Group PLC, the prenatal vitamin Nexa Select, and Zolpimist from NovaDel Pharma and ECR Pharmaceuticals.

  • Shire to submit new drug application to FDA for dry eye disease.  // Optometry Times;Jun2014, Vol. 6 Issue 6, p6 

    The article reports on the plan by pharmaceutical company Shire to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lifitegrast for the treatment of dry eye disease in adults in first-quarter 2015.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics